These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 38403950)
1. Mexidol, Cytoflavin, and succinic acid derivatives as antihypoxic, anti-ischemic metabolic modulators, and ergogenic aids in athletes and consideration of their potential as performance enhancing drugs. Jędrejko K; Catlin O; Stewart T; Muszyńska B Drug Test Anal; 2024 Feb; ():. PubMed ID: 38403950 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic analysis of the neuroprotective medicines in the treatment of ischemic stroke]. Yagudina RI; Kulikov AY; Krylov VA; Solovieva EY; Fedin AI Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(7):60-68. PubMed ID: 31464291 [TBL] [Abstract][Full Text] [Related]
3. [Comparative studies of antihypoxic, neuroprotective and analgesic action of succinate-containing drugs]. Iasnetsov VV; Prosvirova EP; Tsublova EG; Iasnetsov VV; Motin VG; Karsanova SK Aviakosm Ekolog Med; 2012; 46(6):41-5. PubMed ID: 23457968 [TBL] [Abstract][Full Text] [Related]
4. [A modern concept of antihypoxic and antioxidant effects of mexidol]. Shchulkin AV Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(12. Vyp. 2):87-93. PubMed ID: 30830123 [TBL] [Abstract][Full Text] [Related]
5. [Antihypoxic effect of 3-hydroxypyridine and succinic acid derivatives and their nootropic action in alloxan diabetes]. Volchegorskiĭ IA; Rassokhina LM; Miroshnichenko IIu Eksp Klin Farmakol; 2011; 74(12):27-32. PubMed ID: 22379879 [TBL] [Abstract][Full Text] [Related]
6. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs. Negro F; Di Trana A; Marinelli S Acta Biomed; 2022 Jan; 92(6):e2021401. PubMed ID: 35075058 [TBL] [Abstract][Full Text] [Related]
7. Metabolic and Body Composition Changes in Ice Hockey Players Using an Ergogenic Drug (Cytoflavin). Zaborova V; Kurshev V; Kryuchkova K; Anokhina V; Malakhovskiy V; Morozova V; Sysoeva V; Zimatore G; Bonavolontà V; Guidetti L; Dronina Y; Kravtsova E; Shestakov D; Gurevich K; Heinrich KM Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829493 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with ischemic stroke]. Zhuravleva MV; Shchukin IA; Fidler MS; Prokofiev AB; Serebrova SY; Vasyukova NS; Demchenkova EY; Arkhipov VV Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12. Vyp. 2):60-66. PubMed ID: 33449535 [TBL] [Abstract][Full Text] [Related]
9. [Anxiolytic and antidepressant effects of 3-oxypiridine and succinic acid derivatives in the acute phase of alloxan-induced diabetes in rats]. Volchegorskiĭ IA; Miroshnichenko IIu; Rassokhina LM; Faĭzullin RM; Malkin MP; Priakhina KE; Kalugina AV Eksp Klin Farmakol; 2014; 77(4):14-20. PubMed ID: 25076754 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of the anxiolytic effects of 3-hydroxypyridine and succinic acid derivatives. Volchegorskii IA; Miroshnichenko IY; Rassokhina LM; Faizullin RM; Malkin MP; Pryakhina KE; Kalugina AV Bull Exp Biol Med; 2015 Apr; 158(6):756-61. PubMed ID: 25894772 [TBL] [Abstract][Full Text] [Related]
11. [Dopaminergic potential of domestic 3-hydroxypyridine and succinic acid derivatives and prospects for their therapeutic «retargeting»]. Volchegorskii IA; Rassokhina LM; Miroshnichenko IU Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8):21-29. PubMed ID: 37655406 [TBL] [Abstract][Full Text] [Related]
12. Unauthorized ingredients in "nootropic" dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents. Jędrejko K; Catlin O; Stewart T; Anderson A; Muszyńska B; Catlin DH Drug Test Anal; 2023 Aug; 15(8):803-839. PubMed ID: 37357012 [TBL] [Abstract][Full Text] [Related]
13. Comparative Analysis of Stress-Protective Activity and Prevention of Fatigue during Physical Load of Standardized Humic Acids from Peat and Officinal Preparations of Succinic Acid in Experiment. Zamoshchina TA; Gostyukhina AA; Zykova MV; Logvinova LA; Prokopova AV; Zaitsev KV; Svetlik MV; Belousov MV; Dygai AM Bull Exp Biol Med; 2023 Jun; 175(2):210-214. PubMed ID: 37464194 [TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of 3-hydroxypyridine and succinic acid derivatives in complex treatment of primary open-angle glaucoma]. Volchegorskiĭ IA; Tur EV; Soliannikova OV; Rykun VS; Sumina MS; Dmitrienko VN; Berdnikova EV Eksp Klin Farmakol; 2012; 75(7):20-6. PubMed ID: 23025048 [TBL] [Abstract][Full Text] [Related]
16. [Modern strategies of protection of hypoxic-ischemic brain damage]. Yanishevsky SN; Tsygan NV; Golokhvastov SY; Andreev RV; Litvinenko IV; Karpova OS; Yakovleva VA Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(12. Vyp. 2):78-86. PubMed ID: 29411750 [TBL] [Abstract][Full Text] [Related]
17. [An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment]. Volchegorskii IA; Izarovskii BV; Shamaeva TN; Izarovskaia IV Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(9):63-71. PubMed ID: 34693691 [TBL] [Abstract][Full Text] [Related]
18. [Anxiolytic and antidepressant effects of emoxipine, reamberin and mexidol in experimental diabetes mellitus]. Volchegorskii IA; Miroshnichenko IY; Rassokhina LM; Faizullin RM; Pryakhina KE Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):52-57. PubMed ID: 28638031 [TBL] [Abstract][Full Text] [Related]
19. [Anxiolytic and antidepressant effects of 3-oxypiridine and succinic acid derivatives in alloxan diabetes]. Volchegorskii LA; Miroshnichenko IY; Rassokhina LM; Faizullin RM; Pryakhina KE; Kalugina AV Ross Fiziol Zh Im I M Sechenova; 2015 Mar; 101(3):258-67. PubMed ID: 26016320 [TBL] [Abstract][Full Text] [Related]
20. Story behind meldonium-from pharmacology to performance enhancement: a narrative review. Schobersberger W; Dünnwald T; Gmeiner G; Blank C Br J Sports Med; 2017 Jan; 51(1):22-25. PubMed ID: 27465696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]